Why Is AEON Stock Rising Today? AEON Biopharma Surges After Appointing Former FDA Official as Acting CRO

AEON Biopharma (NYSE American: AEON) shares rose 10.74% in intraday trading Tuesday after the company named former FDA Deputy Director Dr. Paul Lee as acting Chief Regulatory Officer.

The announcement, released Monday, signals a push to strengthen AEON's regulatory strategy as it advances ABP-450, a biosimilar candidate to Allergan's BOTOX for therapeutic use.

What Did AEON Biopharma Announce?

The company designated Paul Lee, M.D., Ph.D. as acting CRO through Clintrex Research LLC, an affiliate of BlueRidge Life Sciences. Dr. Lee previously served as Deputy Director of the FDA's Office of Neuroscience and has already been advising AEON on the regulatory and clinical development strategy for ABP-450.

The appointment formalizes a relationship that was already in place. Rather than bringing on a completely new hire, AEON is transitioning its existing regulatory advisor into a leadership role, giving the company someone with deep FDA experience at the helm of its biosimilar program.

In his new capacity, Dr. Lee will lead regulatory strategy, guide the company's interactions with the FDA, and work with AEON's analytical, CMC and clinical teams as ABP-450 progresses under the 351(k) biosimilar pathway.

Why Does The Regulatory Leadership Change Matter?

The timing is significant. AEON is approaching a critical inflection point in its biosimilar development program. Earlier in 2026, the company held a successful BPD Type 2a meeting with the FDA, receiving support for its analytical similarity strategy. A planned Type 2b interaction is expected to help inform the next phase of ABP-450's development, including clinical pharmacology and comparative clinical study requirements.

On the science front, AEON has been building out its comparability dataset. In August, the company reported expanded structural data showing 100% amino acid identity between ABP-450 and BOTOX across all analyzed regions, with peptide-mapping coverage increased to 98% of the primary sequence. Preliminary analysis also demonstrated preservation of the critical disulfide bond architecture required for toxin activation.

Dr. Lee's FDA background may be particularly valuable at this juncture. Navigating the 351(k) pathway requires close agency engagement, and having a former FDA neuroscience leader shape the regulatory approach could streamline the path to a Biologics License Application. The company is targeting full-label therapeutic biosimilar approval, aiming at a U.S. therapeutic neurotoxin market that exceeds $3 billion annually.

What Should Investors Watch Next?

The next near-term catalyst is the FDA BPD Type 2b interaction. Feedback from that meeting will help define what additional studies AEON needs to complete before it can file a BLA. Investors will want to assess how the agency's guidance shapes the development timeline and capital requirements.

Cash runway is another consideration. The company raised approximately $13.6 million in net proceeds from a July 2026 public offering, which management said extends the cash runway into the first quarter of 2027. That offering also restored AEON's compliance with NYSE American listing standards. Depending on the scope of studies required post-Type 2b, further financing may be needed.

Trading volume was extremely elevated during the session, running at approximately 16.8 times the 20-day average. The spike suggests the move drew broad investor attention, though the magnitude of the gain may reflect the stock's micro-cap status and the compounding effect of recent positive developments — the structural data readout, the regulatory leadership hire, and ongoing biosimilar progress all clustering within a short window.

With Dr. Lee now in the acting CRO role, the focus shifts to how quickly AEON can convert analytical progress into a clear clinical development plan and what the FDA's next feedback cycle reveals.